Timing of Antiretroviral Therapy for HIV-1 Infection and TuberculosisDiane V. Havlir, Ian Sanne, Michelle A. Kendall et al.|New England Journal of Medicine|2011Cited by 541
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialBeatriz Grinsztejn, Myron S. Cohen, N. Kumarasamy et al.|The Lancet Infectious Diseases|2014Cited by 513
Improved Neuropsychological and Neurological Functioning Across Three Antiretroviral Regimens in Diverse Resource-Limited Settings: AIDS Clinical Trials Group Study A5199, the International Neurological StudyK. Robertson, Aspara Nair, Hongyu Jiang et al.|Clinical Infectious Diseases|2012Cited by 61
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settingsKevin Robertson, Pim Brouwers, Johnstone Kumwenda et al.|Journal of NeuroVirology|2011Cited by 45
Herpes Simplex Virus Type 2 Acquisition Among HIV-1–Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS StudyConnie Celum, Ting Hong, Anne Cent et al.|The Journal of Infectious Diseases|2017Cited by 10